Cytodyne sues New York Times
This article was originally published in The Tan Sheet
Executive Summary
Lawsuit filed in Newark, N. J. federal court June 24 by former Xenadrine marketer alleges New York Times reporter Ford Fessenden "selectively excluded scientific information regarding clinical testing performed" on Xenadrine in June 23 article on dietary supplements. Complaint alleges Fessenden failed to contact Cytodyne for clarification and "accepted only a one-sided, inaccurate and untruthful version of the 'facts.'" Suit refers to recent controversy involving reporter Jayson Blair and alleges newspaper has "engaged in a pattern of failing to supervise its reporters and failing to check the accuracy and completeness" of stories. In response, Times says it is "confident" in the accuracy of its article, "which was based on court records and judicial decisions"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.